PatientsVille.com Logo

DYSARTHRIA and Thyroid

PatientsVille

DYSARTHRIA Symptoms and Causes

Many disorders can affect our ability to speak and communicate. They range from saying sounds incorrectly to being completely unable to speak or understand speech. Causes include

  • Hearing disorders and deafness
  • Voice problems, such as dysphonia or those caused by cleft lip or palate
  • Speech problems like stuttering
  • Developmental disabilities
  • Learning disorders
  • Autism spectrum disorder
  • Brain injury
  • Stroke

Some speech and communication problems may be genetic. Often, no one knows the causes. By first grade, about 5 percent of children have noticeable speech disorders. Speech and language therapy can help.

NIH: National Institute on Deafness and Other Communication Disorders

Check out the latest treatments for DYSARTHRIA

DYSARTHRIA treatment research studies

Thyroid clinical trials, surveys and public health registries


Find Drug Side Effect reports



Thyroid Side Effects

Fatigue (48)
Hypothyroidism (38)
Alopecia (37)
Product Formulation Issue (23)
Headache (23)
Palpitations (22)
Diarrhoea (21)
Feeling Abnormal (21)
Dizziness (21)
Dyspnoea (21)
Product Substitution Issue (20)
Pain (20)
Chest Pain (20)
Asthenia (19)
Weight Increased (19)
Product Quality Issue (18)
Blood Thyroid Stimulating Hormone Increased (17)
Blood Pressure Increased (17)
Heart Rate Increased (17)
Depression (17)
Insomnia (17)
Myalgia (16)
Nausea (15)
Hypertension (15)
Arthralgia (15)
Atrial Fibrillation (15)
Dry Skin (14)
Rash (13)
Tremor (12)
Urticaria (12)
Pain In Extremity (12)
Malaise (12)
Abdominal Pain Upper (11)
Anxiety (11)
Condition Aggravated (11)
Hyperhidrosis (11)
Thyroid Function Test Abnormal (10)
Muscle Spasms (9)
Deep Vein Thrombosis (9)
Flatulence (9)
Hyperthyroidism (9)
Heart Rate Irregular (9)
Confusional State (8)
Blood Thyroid Stimulating Hormone Decreased (8)
Constipation (8)
Vomiting (8)
Weight Decreased (8)
Oedema Peripheral (8)
Extrasystoles (8)
Suicidal Ideation (7)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

DYSARTHRIA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting Intensive Dysarthria Sessions in Adults and Children With Down Syndrome
Conditions: Dysarthria;   Down Syndrome
Intervention: Behavioral: Speech sessions
Outcome Measure: Speech intelligibility
2 Unknown  Efficacy of Voice Treatment for Parkinson's Disease
Conditions: Parkinson's Disease;   Dysphagia;   Dysarthria
Interventions: Behavioral: Voice/Respiration Treatment;   Behavioral: Speech/Articulation Treatment;   Behavioral: No intervention (PD);   Behavioral: HC control
Outcome Measure: Voice intensity; voice fundamental frequency; articulatory acoustics; physiological voice function; speech intelligibility; swallowing function; non-verbal communication behaviors; limb function; neural imaging; neuropsychological functioning
3 Recruiting Central Mechanisms in Speech Motor Control Studied With H215O PET
Conditions: Communication Disorder;   Healthy;   Stuttering;   Tourette Syndrome;   Voice Disorder
Intervention:
Outcome Measure:
4 Recruiting Emotional Prosody Treatment in Parkinson's
Condition: Parkinson Disease
Interventions: Behavioral: Emotional prosodic treatment;   Behavioral: Standard prosodic treatment
Outcome Measure: Change from pre to post treatment in perceptual and acoustic analysis of sentences spoken in emotional tones.
5 Recruiting Effect of DBS on Quality of Life in Dyskinetic Cerebral Palsy
Condition: Dyskinetic Cerebral Palsy Due to Perinatal Hypoxia
Intervention:
Outcome Measures: Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD);   Burke-Fahn-Marsden-Dystonia Rating Scale movement and disability;   Dyskinesia Impairment Scale;   Tardieu Scale;   Frenchay Dysarthria Assessment;   SF-36;   Strengths and Difficulties Questionnaire;   Snijders-Oomen-Non-Verbal-Intelligence Test (SON-R);   Attentional Network Test (ANT);   Non-Verbal-Learning Test (NVLT);   Wong Baker Faces;   Family Scale (FaBel);   CPCHILD;   Canadian Occupational Performance Measure (COPM);   Gross Motor Function Measure (GMFM-66);   Gross Motor Function Classification System (GMFCS)
6 Not yet recruiting Clinical Study to Evaluate the Safety and Efficacy Mesenchymal Stem Cell in Cerebellar Ataxia
Condition: Cerebellar Ataxia
Intervention: Biological: Intravenous transfer of Mesenchymal Stem Cell ( MSCs )
Outcome Measures: improve in INTERNATIONAL CO-OPERATIVE ATAXIA RATING SCALE;   Balance test;   Tremor Rating Scale;   quality of life
7 Recruiting Intrathecal Transplantation of Mesenchymal Stem Cell in Patients With ALS
Condition: Amyotrophic Lateral Sclerosis
Intervention: Biological: intrathecal injection
Outcome Measures: Fever;   Unconscious;   Vomiting;   ALS-FRS;   FVC
8 Not yet recruiting Intraventricular Transplantation of Mesenchymal Stem Cell in Patients With ALS
Condition: Amyotrophic Lateral Sclerosis
Intervention: Biological: Intraventricular injection
Outcome Measures: fever;   unconsciousness;   brain hematoma;   vomiting;   ALS-FRS;   EMG-NCV
9 Recruiting Posterior Fossa Mutism on Quality of Life
Condition: Posterior Fossa Mutism
Intervention:
Outcome Measures: Quality of Life;   quality of life in terms of anger, anxiety, depression, fatigue, social functioning, pain and stigma
10 Recruiting Longitudinal Study of Cognition With Niemann-Pick Disease, Type C
Condition: Niemann-Pick Disease, Type C
Intervention:
Outcome Measure: Composite score of neurocognitive measures
11 Recruiting Alternatives for Reducing Chorea in HD
Condition: Chorea Associated With Huntington Disease
Intervention: Drug: SD-809
Outcome Measures: Overall incidence of adverse events (AEs), serious AEs, severe AEs, drug related AEs, AEs leading to withdrawal;   Incidence of adverse events (AEs), serious AEs, severe AEs, drug related AEs, AEs leading to withdrawal during the titration period in Rollover subjects;   Incidence of adverse events (AEs), serious AEs, severe AEs, drug related AEs, AEs leading to withdrawal during the dose adjustment period in Switch subjects;   Incidence of adverse events (AEs), serious AEs, severe AEs, drug related AEs, AEs leading to withdrawal during long term treatment;   Changes from baseline in clinical laboratory parameters (hematology, chemistry and urinalysis);   Changes from baseline in UHDRS, UPDRS (Dysarthria), BARS, HADS, ESS, C-SSR, and MoCA;   Changes from baseline in vital signs;   Changes from baseline in ECG parameters and abnormal findings;   Duration of time to achieve stable dosing of SD-809 ER
12 Unknown  Deep Brain Stimulation (DBS) For Parkinson's Disease: Caudal Zona Incerta Versus Subthalamic Nucleus
Condition: Parkinson's Disease
Intervention: Procedure: deep brain stimulation
Outcome Measures: Improvement of scores (UPDRS III, PDQ-39) in Stim-ON and Med-OFF in a standard clinical check-up (CAPSIT) 12 and 24 months after operation compared to primary inclusion examination;   Changes in Dysarthria, other symptoms (subitems of UPDRS-III), dyskinesia (UPDRS-IV), impairment of gait, on-off fluctuations
13 Unknown  Efficacy of Riluzole in Hereditary Cerebellar Ataxia
Condition: Cerebellar Ataxia
Interventions: Drug: riluzole;   Other: Placebo comparator
Outcome Measures: Scale for the assessment and rating of ataxia (SARA);   Baropodometric parameters;   Quality of life;   Anxiety;   Depression